UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 486

Sortiert nach

Selective RET kinase inhibition for patients with RET-altered cancers

Annals of oncology, 2018-08, Vol.29 (8), p.1869-1876

2018

Volltextzugriff (PDF)

391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers

European journal of cancer (1990), 2014-11, Vol.50, p.125-125

2014

Volltextzugriff (PDF)

The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S145

2016

Volltextzugriff (PDF)

The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S144

2016

Volltextzugriff (PDF)

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent

Clinical cancer research, 1998-12, Vol.4 (12), p.3083-3088

1998

Volltextzugriff (PDF)

Characterization of a Mechanism-Based Inhibitor of NAD(P)H:Quinone Oxidoreductase 1 by Biochemical, X-ray Crystallographic, and Mass Spectrometric Approaches

Biochemistry (Easton), 2001-12, Vol.40 (50), p.15135-15142

2001

Volltextzugriff (PDF)

Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1

Molecular pharmacology, 2001-02, Vol.59 (2), p.263-268

2001

Volltextzugriff (PDF)

ARSENATE TOXICITY IN HUMAN ERYTHROCYTES: CHARACTERIZATION OF MORPHOLOGIC CHANGES AND DETERMINATION OF THE MECHANISM OF DAMAGE

Journal of Toxicology and Environmental Health, Part A, 1998-03, Vol.53 (5), p.345-355

1998

Volltextzugriff (PDF)

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones

Biochemical pharmacology, 2001-06, Vol.61 (12), p.1509-1516

2001

Volltextzugriff (PDF)

Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations

European journal of cancer (1990), 2022-10, Vol.174, p.S81-S81

2022

Volltextzugriff (PDF)

In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

European journal of cancer (1990), 2022-10, Vol.174, p.S81-S81

2022

Volltextzugriff (PDF)

Effects of parenteral cysteine and glutathione feeding in a baboon model of severe prematurity

The American journal of clinical nutrition, 2000-12, Vol.72 (6), p.1548-1557

2000

Volltextzugriff (PDF)

162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations

European journal of cancer supplements, 2010, Vol.8 (7), p.56-56

2010

Volltextzugriff (PDF)

Differential Involvement of Caspases in Hydroquinone-Induced Apoptosis in Human Leukemic HL-60 and Jurkat Cells

Toxicology and applied pharmacology, 2001-09, Vol.175 (2), p.95-103

2001

Volltextzugriff (PDF)

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms

Chemico-biological interactions, 2000-12, Vol.129 (1), p.77-97

2000

Volltextzugriff (PDF)

Handbook of Standards and Resources for Spoken Language Systems: Spoken Language Characterization

2020

Volltextzugriff (PDF)

442 - The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S145

2016

Volltextzugriff (PDF)

441 - The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S144

2016

Volltextzugriff (PDF)

Interactions of rat red blood cell sulfhydryls with arsenate and arsenite

Journal of toxicology and environmental health, 1995-11, Vol.46 (3), p.379-397

1995

Volltextzugriff (PDF)

Structures of Recombinant Human and Mouse NAD(P)H:Quinone Oxidoreductases: Species Comparison and Structural Changes with Substrate Binding and Release

Proceedings of the National Academy of Sciences - PNAS, 2000-03, Vol.97 (7), p.3177-3182

2000

Volltextzugriff (PDF)

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H :quinone oxidoreductase 1

Pharmacogenetics (London), 1999-02, Vol.9 (1), p.113-121

1999

Volltextzugriff (PDF)

Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development

Frontiers in bioscience, 2000, Vol.5, p.D639

2000

Volltextzugriff (PDF)

Structure-Based Development of Anticancer Drugs: Complexes of NAD(P)H:Quinone Oxidoreductase 1 with Chemotherapeutic Quinones

Structure (London), 2001-08, Vol.9 (8), p.659-667

2001

Volltextzugriff (PDF)

Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells

Cancer research (Chicago, Ill.), 2002-03, Vol.62 (5), p.1420-1424

2002

Volltextzugriff (PDF)

Effect of Arsenic Exposure on Alveolar Macrophage Function .2. Effect of Slightly Soluble Forms of as(III) and as(V)

Environmental research, 1995, Vol.68 (1), p.59-67

1995

Volltextzugriff (PDF)

1 – 25 von 486

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(408)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(485)
Japanisch
(11)
Polnisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Publisher or Other Site
(226)
eBooks on EBSCOhost
(132)
Nexis Uni
(124)
De Gruyter eBooks
(123)
Free E-Journal (出版社公開部分のみ）
(108)
Ingenta
(72)
Ebook Central Perpetual and DDA
(55)
MEDLINE
(45)
IngentaConnect Journals
(34)
PAIS Index
(33)
ScienceDirect
(32)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(27)
Journals@Ovid Ovid Full Text
(27)
Wiley-Blackwell Full Collection
(12)
ProQuest Dissertations & Theses A&I
(9)
Wiley Online Library Full Collection 2018
(9)
JSTOR
(8)
Oxford Journals
(7)
IEEE Xplore
(6)
Oxford Journals 2020 Medicine
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Selective RET kinase inhibition for patients with RET-altered cancers

391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers

The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent

Characterization of a Mechanism-Based Inhibitor of NAD(P)H:Quinone Oxidoreductase 1 by Biochemical, X-ray Crystallographic, and Mass Spectrometric Approaches

Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1

ARSENATE TOXICITY IN HUMAN ERYTHROCYTES: CHARACTERIZATION OF MORPHOLOGIC CHANGES AND DETERMINATION OF THE MECHANISM OF DAMAGE

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones

Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations

In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

Effects of parenteral cysteine and glutathione feeding in a baboon model of severe prematurity

162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations

Differential Involvement of Caspases in Hydroquinone-Induced Apoptosis in Human Leukemic HL-60 and Jurkat Cells

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms

Handbook of Standards and Resources for Spoken Language Systems: Spoken Language Characterization

442 - The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

441 - The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

Interactions of rat red blood cell sulfhydryls with arsenate and arsenite

Structures of Recombinant Human and Mouse NAD(P)H:Quinone Oxidoreductases: Species Comparison and Structural Changes with Substrate Binding and Release

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H :quinone oxidoreductase 1

Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development

Structure-Based Development of Anticancer Drugs: Complexes of NAD(P)H:Quinone Oxidoreductase 1 with Chemotherapeutic Quinones

Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells

Effect of Arsenic Exposure on Alveolar Macrophage Function .2. Effect of Slightly Soluble Forms of as(III) and as(V)

Suchergebnisse filtern